Beckman Coulter Highlights “Innovation in Molecular Diagnostics Workflow” at ECCMID 2016

Beckman Coulter is proudly showcasing the proven workflow and ease-of-use benefits of its DxN VERIS Molecular Diagnostics System at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands, (9-12 April 2016).

The unique DxN VERIS system, that integrates sample introduction, nucleic acid extraction, reaction setup, real‐time PCR amplification and detection instrument, can be seen at booth #52, and, at the company’s “Innovation in MDx: Workflow Redesign and Assay Performance” symposium where leading European experts in molecular diagnostics will describe their use of the DxN VERIS and its assays and highlight the workflow and ease-of use benefits experienced.

Chaired by Rafael Delgado, M.D., head of clinical microbiology department, Hospital Universitario 12 de Octubre, Madrid, Spain, the symposium will be held on 12 April 2016 | 9:00 – 11:00 Hall B with the following agenda: Workflow transformed: A new, fully-automated system for molecular diagnostics Pr. Jörg Hofmann, Labor Berlin Charitès-Vivantes GmbH, Berlin, Germany Quantifying HIV-1 RNA with DxN VERIS, a new, fully-automated system for molecular diagnostics Pr. Jacques Izopet, Hospital Purpan, Toulouse, France

Performance of DxN VERIS Molecular Diagnostics System for HCV viral load quantification in the clinical setting Dr. Alessandra Lombardi, Sacco Hospital Milan, Italy DxN VERIS in routine laboratory use: A customer experience Pr. Vincent Thibault, Centre Hospitalier Universitaire de Rennes, Rennes, France

(Please note that symposium places must be reserved in advance – please contact Tiffany Page, Senior Pan European Marketing Manager Molecular Diagnostics, Email: info@beckmanmolecular.com)

“The Symposium presentations reinforce recent independent performance studies undertaken at hospitals throughout Europe which confirmed that there is no lengthy system set-up – all consumables/reagents are refrigerated on-board and assays supplied in a unique, single cartridge system. Furthermore, one hospital study showed that technicians can be up and running on the system after just 20 minutes training,” explained John Sweeney, senior vice president of molecular diagnostics and CSO of Beckman Coulter Diagnostics.

“By reducing manual intervention and automating the steps from sample loading to reporting of results, DxN VERIS frees up staff to perform other, more value-added tasks,” he continues, “The true, single‐sample, random‐access capability of DxN VERIS, means that multiple assays and samples can be run at the same time, delivering faster, accurate clinical information. Improving workflow and diagnostic decision-making in this way enhances the lab’s service to both patients and its clinical customers.”

With no empty wells, unlike traditional batch‐plate systems, wastage and consumable costs are reduced. Tests can be up and running in under 10 minutes and auto‐verified results in 70 minutes.

The growing menu of CE-marked assays includes the: VERIS HIV‐1 Assay, for quantitative detection of Human Immunodeficiency Virus type 1 (HIV‐1) in plasma; VERIS HCV Assay, for quantitative measurement of Hepatitis C Virus (HCV) in human plasma; VERIS HBV Assay, for quantitative measurement of Hepatitis B Virus (HBV) in human plasma and serum and VERIS CMV Assay, for the quantitative determination of human Cytomegalovirus (CMV) in plasma. Assays for sexually transmitted diseases/women’s health and Hospital Acquired Infections are in development. VERIS assays are developed in compliance with CLSI guidelines and ISO standards, and calibrated to WHO standards. Each quantitative test offers a broad measuring interval and high sensitivity.